Contentious hearings to consider Robert F. Kennedy Jr. to lead the Department of Health and Human Services this week have ...

LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the ...

View of Moderna company office entrance exterior with logo sign in Cambridge ... Moderna's partnership with Merck on a cancer vaccine shows potential, but it is years away from generating ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Merck & Company (MRK – Research Report), with a ...

Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company (MRK – Research Report) yesterday and set a price target of ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV ...

The company forecasts full-year 2025 adjusted EPS of $8.88 to $9.03, below the consensus estimate of $9.21. Revenue is projected to be between $64.1 billion and $65.6 billion, also lower than the ...

Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name drugs such as Keytruda, and the myriad of commercials the company shows on ...

Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...